NTT-COMMUNICATIONS
8.4.2021 04:02:11 CEST | Business Wire | Press release
NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group, announced today that it has succeeded in a trial sharing of production-line data related to CO2 emissions via a prototype platform that enables interconnection via IDS standards which support data sovereignty in GAIA-X data ecosystem. The trial data, which normally would not be available for sharing due to its high confidentiality even though partners engaged in actual business would need to perform CO2 emissions calculations, was transmitted securely to designated sites in Germany and Japan from Switzerland Innovation Park Biel/Bienne in Switzerland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407006040/en/
GAIA-X is an initiative announced by the German and French governments in October 2019 to support data sharing via infrastructure that ensures data protection, transparency, reliability and interoperability to protect the rights of European companies, governments, institutions and citizens.
NTT Com conducted the trial under the assumption that such data will be used by companies engaged in actual business to review their manufacturing methods to achieve greater decarbonization. The prototype platform, which enables interconnection with IDS Connectors, also is equipped with DATA Trust® , a mechanism for the secure sharing of highly confidential data.
The trial involved the sharing of electricity-consumption data that business partners typically would use to calculate CO2 emissions generated during the manufacturing of specific products. The trial confirmed that NTT’s platform can share such data securely with only those parties permitted by law or contract.
The prototype was developed using Nippon Telegraph and Telephone Corporation (Software Innovation Center)'s business-to-business data distribution technology, in cooperation with Robot Revolution & Industrial IoT Initiative (RRI), International Data Spaces Association (IDSA), Fraunhofer-Gesellschaft, Switzerland Innovation Park Biel/Bienne and Japan Innovation Park.
NTT Com plans to exhibit the trial results at the joint booth of IDSA and RRI during the Hannover Messe industrial fair in Germany from April 12-16.
“Japan is very close to Europe in the field of industry, with a strong experience in automotive, steel, or manufacturing,” said Hubert Tardieu, Chairman of GAIA-X AISBL. “The main objective in every industry is nowadays data sharing and service orchestration like in GAIA-X. NTT Communications starts with a first run in data sharing between, Japan, Germany and Switzerland, using the IDS standard which supports data sovereignty in GAIA-X data ecosystems. We are proud at GAIA-X AISBL to strongly support the launching of the japan Hub trough NTT Communications and start more use cases around GAIA-X.”
Going forward, NTT Com will build a test environment in Japan to connect with GAIA-X and start interoperability tests with multiple partner companies around the world this summer. If all goes well, NTT Com hopes to launch an official platform within the fiscal year ending in March 2022. The launch would be coordinated with organizations and groups involved with international data distribution, including Data Society Alliance, OPC Foundation Japan, RRI, GAIA-X AISBL and IDSA.
Data utilization has become indispensable for initiatives such as global decarbonization, the early achievement of the United Nations’ Sustainable Development Goals and the strengthening of industries. At the same time, however, legal systems and technologies to regulate and manage data use are being developed around the world, one of which is GAIA-X, to prevent the leakage of corporate and national secrets and to protect data sovereignty.
In the future, it is expected that companies will be required to use GAIA-X to send and receive highly confidential data to and from business partners in European countries. This means that companies unable to use GAIA-X would not be able to do business with European partners if sensitive data sharing were involved. NTT Com’s envisioned platform, however, would enable such companies to easily connect to GAIA-X without have to spend valuable time and money on an acceptable data-sharing solution.
About NTT Communications
NTT Communications solves the world's technology challenges by helping enterprises overcome complexity and risk in their ICT environments with managed IT infrastructure solutions. These solutions are backed by our worldwide infrastructure, including industry leading, global tier-1 public and private networks reaching over 190 countries/regions, and more than 500,000m2
of the world's most advanced data center facilities. Our global professional services teams provide consultation and architecture for the resiliency and security required for your business success, and our scale and global capabilities in technology world are unsurpassed. Combined with NTT Ltd., NTT Data, and NTT DOCOMO, we are NTT Group.
www.ntt.com
| Twitter@NTT Com | Facebook@NTT Com | LinkedIn@NTT Com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407006040/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
